There are 2934 resources available
Adjuvant therapy or a combination
Presenter: Mario Mandala
Session: Neo-adjuvant vs. adjuvant therapy or combination for locoregional / oligometastatic melanoma
Resources:
Slides
Webcast
3623 - Phase II Study of Pembrolizumab with Enzalutamide (Enz) in Metastatic, Castration Resistant Prostate Cancer (mCRPC): 30 patient expansion with examination of tumor infiltrating immune cells and fecal microbiota
Presenter: Julie Graff
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
1823 - Preliminary results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
Presenter: Scott Tagawa
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
5118 - Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study
Presenter: Johann de Bono
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
1522 - A Comprehensive Model of Genetic-Features Predicts Outcome of Personalized Adjuvant Treatment in Resected EGFR-mutant Stage II-IIIA NSCLC: Results from a Phase 3 Trial (CTONG 1104-ADJUVANT)
Presenter: Yi-Long Wu
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
2495 - Docetaxel for hormone-naïve prostate cancer (PCa): results from long-term follow-up of non-metastatic (M0) patients in the STAMPEDE randomised trial (NCT00268476)
Presenter: Nicholas James
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
1910 - Patient-Reported Outcomes (PROs) From TITAN: a Phase 3, Randomized, Double-Blind Study of Apalutamide (APA) Versus Placebo (PBO) Added to Androgen Deprivation Therapy (ADT) in Patients (pts) With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Presenter: Neeraj Agarwal
Session: Poster Discussion – Genitourinary tumours, prostate
Resources:
Abstract
1920 - Differential expression of B7-H4, VISTA, B7-H6, HHLA2, IDO-1, PD-L1 and CD8 in EGFR mutant and wild-type lung adenocarcinoma
Presenter: Shaorong Yu
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
3721 - Randomized phase II trial of CODE or AP after chemoradiotherapy for LD-SCLC: long-term survival and toxicity analysis
Presenter: Ikuo Sekine
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
2782 - Efficacy evaluation of concurrent nivolumab addition to a first-line, concurrent chemo-radiotherapy regimen in unresectable locally advanced NSCLC – Results from the European Thoracic Oncology Platform (ETOP 6-14) NICOLAS phase II trial.
Presenter: Solange Peters
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract